Patrick Chin, MD
Ophthalmology · Westwood, NJNPI 1396702783
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.9%), other and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Glaukos Corporation at 55.7% of the total. Reporting peaked in 2024 at $5,031 and has fallen 80.8% since, to $966 in 2025. Among ophthalmology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 160 payments — averaging $59.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$5K
- Johnson & Johnson Surgical Vision, Inc.$1K
- AbbVie$714
- Rxsight Inc$445
- Bausch & Lomb Americas Inc.$274
- Alcon$208
- plus $1K from 19 others
Across 120 payments — averaging $982.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$118K
What the payments were for
- Travel & lodging$7878%
- Food & beverage$4,52848%
- Other$4,12844%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 12 | $5,256 |
| Johnson & Johnson Surgical Vision, Inc. | 9 | $1,315 |
| AbbVie(2 entities) | 38 | $714 |
| Rxsight Inc | 9 | $445 |
| Bausch & Lomb Americas Inc. | 10 | $274 |
| Alcon | 10 | $208 |
| Sun Pharmaceutical Industries Inc. | 11 | $166 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $144 |
| Oyster Point Pharma, Inc. | 7 | $128 |
| Sight Sciences, Inc. | 3 | $126 |
| Novartis | 7 | $117 |
| Kala Pharmaceuticals, Inc. | 7 | $99 |
| Aerie Pharmaceuticals, Inc. | 6 | $86 |
| Johnson & Johnson Vision Care, Inc. | 3 | $72 |
| Tarsus Pharmaceuticals, Inc. | 3 | $57 |
| Shire North American Group Inc | 3 | $40 |
| Mallinckrodt Hospital Products Inc. | 2 | $32 |
| Ocular Therapeutix, Inc. | 2 | $31 |
| Amgen | 2 | $26 |
| NEW World Medical,inc. | 1 | $22 |
| Eyevance Pharmaceuticals LLC | 1 | $22 |
| Dompe US, Inc. | 1 | $19 |
| Coopervision Inc. | 1 | $18 |
| Harrow Eye, LLC | 1 | $13 |
| AstraZeneca | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iDose$4,300
- Tecnis Multifocal Family of 1-piece IOLS$1,037
- Tecnis 1-piece IOL$912
- Tecnis Symfony IOL$912
- RXSIGHT CONTACT LENS$354
- RXSIGHT INJECTOR CARTRIDGE$354
- RXSIGHT INJECTOR HANDPIECE$354
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$354
- LIGHT ADJUSTABLE LENS (LAL)$354
- enVista MX60 IOL$255
- iStent$198
- iDoseTR$198
- IACCESS$158
- iStent inject W$158
- KXL System$158
- Photrexa$158
- iStent Trabecular Micro-Bypass Stent System$152
- iStent inject Trabecular Micro-Bypass Stent System$152
- LUMIGAN$125
- COMBIGAN$125
How this compares
$9,443 in reported general payments places this provider in the 90th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 46 | $64,739 |
| LumiganBimatoprost | 88 | $39,434 |
| XiidraLifitegrast | 12 | $22,740 |
| TyrvayaVarenicline Tartrate | 25 | $22,287 |
| ProlensaBromfenac Sodium | 59 | $21,262 |
| Bromfenac Sodium | 78 | $16,730 |
| RocklatanNetarsudil Mesylat/Latanoprost | 36 | $14,536 |
| Travoprost | 48 | $9,029 |
| IlevroNepafenac | 19 | $7,091 |
| CombiganBrimonidine Tartrate/Timolol | 26 | $6,535 |
| RhopressaNetarsudil Mesylate | 11 | $4,132 |
| Latanoprost | 207 | $2,593 |
| Timolol Maleate | 78 | $2,479 |
| Brimonidine Tartrate | 26 | $2,243 |
| Prednisolone Acetate | 50 | $2,097 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $714 | $110,708160 claims |
| Bausch & Lomb Americas Inc.Xiidra | $274 | $22,74012 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $128 | $22,28725 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $144 | $21,26259 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $86 | $18,66747 claims |
| NovartisIlevro | $117 | $7,09119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Westwood
- Jai ParekhWoodland Park$2M
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Cynthia MatossianPennington$655K
- Eric MannDover$604K
- Brett BieloryRutherford$477K
- Albert KhouriNewark$428K
- Robert FechtnerNewark$324K
- Rajen DesaiFreehold$311K
- Douglas GraysonIselin$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.